CAJ | 학술논문

氯吡格雷是临床常用抗血小板聚集药物，其疗效显著，但存在明显的个体差异。该差异可导致氯吡格雷抗血小板聚集药效下降而引起心血管缺血事件，或使其药效增强而引起出血等不良反应。细胞色素P4502C19倡17（ CYP2 C19倡17）基因突变可使代谢酶活性增强，氯吡格雷活性代谢产物暴露增加，使其药效增强。本文系统地综述了近几年国内外CYP2 C19倡17基因突变与氯吡格雷的疗效关系的研究，为临床个体化用药提供相关参考依据。
록필격뢰시림상상용항혈소판취집약물，기료효현저，단존재명현적개체차이。해차이가도치록필격뢰항혈소판취집약효하강이인기심혈관결혈사건，혹사기약효증강이인기출혈등불량반응。세포색소P4502C19창17（ CYP2 C19창17）기인돌변가사대사매활성증강，록필격뢰활성대사산물폭로증가，사기약효증강。본문계통지종술료근궤년국내외CYP2 C19창17기인돌변여록필격뢰적료효관계적연구，위림상개체화용약제공상관삼고의거。
Clopidogrel is one of the most commonly used anti -platelet drugs in clinical.But it shows the significant individual differences during effective anti-platelet therapy.The differences induced can′t be effective anti -platelet aggregate that caused cardiovascular ischemic events, or may enhanced the efficacy of clopidogrel and caused bleeding.The study found cytochrome P 450 2 C19*17 ( CYP2 C19*17 ) variant can enhance the activity of metabolizing enzymes , increasing the active metabolites exposed to clopidogrel , thereby enhanced the efficacy of clo-pidogrel.This article systematically summarizes domestic and foreign re-searches about the relationship of CYP2C19*17 variant and the efficacy of clopidogrel in order to provide some suggestions for personalized medi-cine.